Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Bolt Biotherapeutics (BOLT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/26/2026: BOLT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $22
1 Year Target Price $22
| 1 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.41M USD | Price to earnings Ratio - | 1Y Target Price 22 |
Price to earnings Ratio - | 1Y Target Price 22 | ||
Volume (30-day avg) 4 | Beta 0.92 | 52 Weeks Range 4.27 - 9.66 | Updated Date 02/26/2026 |
52 Weeks Range 4.27 - 9.66 | Updated Date 02/26/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -22.21 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -355.14% |
Management Effectiveness
Return on Assets (TTM) -32.04% | Return on Equity (TTM) -81.98% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -1065573 | Price to Sales(TTM) 1.81 |
Enterprise Value -1065573 | Price to Sales(TTM) 1.81 | ||
Enterprise Value to Revenue 0.23 | Enterprise Value to EBITDA 0.93 | Shares Outstanding 1919441 | Shares Floating 1641141 |
Shares Outstanding 1919441 | Shares Floating 1641141 | ||
Percent Insiders 7.11 | Percent Institutions 31.23 |
Upturn AI SWOT
Bolt Biotherapeutics
Company Overview
History and Background
Bolt Biotherapeutics was founded in 2015 with the goal of developing a new class of cancer therapies. The company's platform focuses on harnessing the immune system to target and destroy cancer cells. Key milestones include the progression of their lead candidates into clinical trials and strategic partnerships.
Core Business Areas
- Oncology Therapeutics: Bolt Biotherapeutics is focused on developing novel immuno-oncology drugs that leverage a proprietary Boltbodyu2122 Bispecific platform. This platform is designed to activate the patient's own immune system to fight cancer.
Leadership and Structure
Bolt Biotherapeutics is led by a management team with experience in biotechnology and drug development. The company operates as a research-focused biopharmaceutical organization, with its structure geared towards clinical development and scientific innovation.
Top Products and Market Share
Key Offerings
- Product Name 1: BNT210 (formerly BDC-210): This is Bolt Biotherapeutics's lead product candidate, a B7-H3-targeting immune-stimulating antibody conjugate (ISAC) for solid tumors. Competitors in the B7-H3 targeting space include Adicet Bio (ADCT), Mersana Therapeutics (MRSN), and others developing similar antibody-drug conjugates or bispecific antibodies. Market share data is not yet publicly available as it is in clinical development.
- Product Name 2: BNT310 (formerly BDC-304): This is another product candidate utilizing the Boltbodyu2122 Bispecific platform, targeting solid tumors. Competitors would be other companies developing bispecific antibodies for oncology. Market share data is not yet publicly available as it is in clinical development.
Market Dynamics
Industry Overview
The immuno-oncology market is a rapidly growing segment of the pharmaceutical industry, driven by significant advancements in understanding cancer biology and the immune system. It is characterized by high R&D investment, intense competition, and a focus on personalized medicine and novel therapeutic modalities.
Positioning
Bolt Biotherapeutics positions itself as a pioneer in developing a new class of immuno-oncology therapeutics with its Boltbodyu2122 Bispecific platform. Its competitive advantage lies in the potential of its ISACs and bispecific antibodies to induce durable anti-tumor responses by engaging both innate and adaptive immune cells.
Total Addressable Market (TAM)
The TAM for oncology therapeutics is vast, measured in hundreds of billions of dollars globally, with immuno-oncology representing a significant and expanding portion. Bolt Biotherapeutics is positioned to capture a portion of this market by addressing unmet needs in various solid tumor indications. However, its current market penetration is negligible as its products are in early-stage clinical development.
Upturn SWOT Analysis
Strengths
- Proprietary Boltbodyu2122 Bispecific platform with potential for novel therapeutic mechanisms.
- Experienced management team with a track record in drug development.
- Focus on a high-growth area of oncology (immuno-oncology).
- Advancement of lead candidates into clinical trials.
Weaknesses
- Limited clinical data for lead candidates, thus unproven efficacy in humans.
- Reliance on external funding and potential dilution from future capital raises.
- Long development timelines and high R&D costs inherent in drug development.
- Lack of diversified product portfolio beyond early-stage candidates.
Opportunities
- Significant unmet medical needs in various solid tumor indications.
- Potential for strategic partnerships and collaborations with larger pharmaceutical companies.
- Advancements in cancer diagnostics and biomarker identification to personalize treatment.
- Expansion of the Boltbodyu2122 platform to other therapeutic areas.
Threats
- Intense competition from established pharmaceutical companies and emerging biotechs in the immuno-oncology space.
- Clinical trial failures or unexpected adverse events leading to program discontinuation.
- Regulatory hurdles and lengthy approval processes.
- Changes in healthcare policy and reimbursement landscapes.
Competitors and Market Share
Key Competitors
- Adicet Bio (ADCT)
- Mersana Therapeutics (MRSN)
- Innovent Biologics (N.A.)
- Bayer AG (BAYRY)
Competitive Landscape
Bolt Biotherapeutics faces a highly competitive landscape in oncology, particularly within immuno-oncology. Its advantages lie in its novel Boltbodyu2122 platform, but it faces disadvantages in terms of its stage of development and the need to prove clinical efficacy against established therapies and innovative approaches from competitors.
Growth Trajectory and Initiatives
Historical Growth: Bolt Biotherapeutics's historical growth has been characterized by its progression from a preclinical-stage company to one with candidates in clinical development. This growth is measured by scientific milestones, advancements in its platform technology, and successful fundraising efforts to fuel its R&D pipeline.
Future Projections: Future growth projections are highly contingent on the successful outcomes of its clinical trials, particularly for BNT210. Positive data could lead to significant value creation and potential partnerships or acquisition opportunities. Analyst estimates for future growth are speculative at this stage.
Recent Initiatives: Recent initiatives likely include the advancement of its lead candidates into new clinical trial phases, exploring new target indications, and potentially forging strategic collaborations to support the development and commercialization of its pipeline.
Summary
Bolt Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology therapies. Its proprietary Boltbodyu2122 platform holds promise, but the company faces significant risks associated with clinical trial outcomes and intense competition. Strong execution in clinical development and successful fundraising are crucial for its future success, while failure in trials or inability to secure funding pose considerable threats.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (e.g., 10-K, 10-Q)
- Company Investor Relations Presentations
- Industry Analyst Reports (where publicly available)
- Biotechnology Databases and News Outlets
Disclaimers:
This analysis is based on publicly available information and is intended for informational purposes only. It does not constitute financial or investment advice. The biotechnology sector is inherently volatile, and investment decisions should be made with the advice of a qualified financial professional after conducting thorough due diligence. Specific financial data and market share figures for clinical-stage companies can be limited and are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bolt Biotherapeutics
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2021-02-05 | CEO, CFO, President, Secretary & Director Mr. William P. Quinn | ||
Sector Healthcare | Industry Biotechnology | Full time employees 40 | Website https://www.boltbio.com |
Full time employees 40 | Website https://www.boltbio.com | ||
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company dBDC-3042, develops dan agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer; and BDC-4182, an next-generation boltbody technology platform that targets claudin 18.2, which is overexpressed in gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc.; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.